NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Cipla Enters 60:40 Joint Venture with Kemwell Biopharma for Global Biologics Expansion
Cipla Limited has entered into a 60:40 joint venture agreement with Kemwell Biopharma to develop, manufacture, and commercialize biologic products for global markets. The partnership leverages Kemwell's US FDA-certified Bangalore facility, which features a 5,000L bioreactor capacity and advanced protein therapeutic labs. Both partners will initially invest up to INR 10 crores in the new entity according to their shareholding ratio. This strategic move aims to strengthen Cipla's portfolio in the high-growth biosimilars and biologics segment.
முக்கிய அம்சங்கள்
Formation of a 60:40 joint venture between Cipla and Kemwell Biopharma for global biologicsInitial investment of up to INR 10 crores to be funded by partners in their respective JV ratiosAccess to Kemwell's US FDA-certified site in Bangalore with 5,000L bioreactor capacityFocus on end-to-end services including R&D, clinical programs, and commercial manufacturing of biosimilars
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic long-term positive as it enhances Cipla's capabilities in the complex biologics market. Monitor the JV's progress in product filings and regulatory approvals for global markets.
Cipla Incorporates Wholly-Owned Step-Down Subsidiary in Saudi Arabia
Cipla Limited has announced the incorporation of a new wholly-owned step-down subsidiary, Cipla Middle East Company, in the Kingdom of Saudi Arabia (KSA) effective March 1, 2026. The entity was established through Cipla (EU) Limited, UK, to facilitate manufacturing and distribution of pharmaceutical products within the region. This strategic move allows Cipla to hold marketing authorizations directly in KSA, strengthening its operational footprint in the Middle East. While initial turnover is not applicable, the 100% control indicates a long-term commitment to the Saudi pharmaceutical market.
முக்கிய அம்சங்கள்
Incorporation of 'Cipla Middle East Company' in Saudi Arabia effective March 1, 2026100% shareholding held by Cipla (EU) Limited, UK, making it a step-down subsidiaryEntity established for manufacturing, distribution, and holding marketing authorizations in KSAStrategic expansion into the Middle East pharmaceutical industry to enhance regional presence
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress in securing marketing authorizations in KSA, as this could drive long-term revenue growth in the Middle East. No immediate action is required as the financial impact will be realized over the coming years.
Cipla to Appoint Achin Gupta as MD & Global CEO for 5-Year Term Starting April 2026
Cipla Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Achin Gupta as Managing Director and Global CEO for a five-year term effective April 1, 2026. The company is also seeking to re-appoint Mr. P.R. Ramesh as an Independent Director for a second five-year term starting July 1, 2026, which includes approval for his continuation beyond the age of 75. Shareholders can cast their votes via remote e-voting from February 24 to March 25, 2026, with results expected by March 30, 2026. This leadership transition marks a significant milestone for the company's long-term executive strategy.
முக்கிய அம்சங்கள்
Appointment of Achin Gupta as MD and Global CEO for a 5-year tenure from April 1, 2026, to March 31, 2031Re-appointment of P.R. Ramesh as Independent Director for 5 years from July 1, 2026, to June 30, 2031E-voting period scheduled between February 24, 2026, and March 25, 2026Cut-off date for shareholder voting eligibility set as February 20, 2026Final results of the postal ballot to be announced on or before March 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the leadership transition and any potential shifts in corporate strategy under the new CEO. Shareholders are encouraged to participate in the e-voting process to express their stance on the proposed appointments.
Cipla's Lanreotide Supply Partner Facility Classified as OAI by USFDA
Cipla Limited has been informed that the USFDA has classified the manufacturing facility of its supply partner, Pharmathen International S.A. in Greece, as Official Action Indicated (OAI). This facility is critical as it supplies Lanreotide Injection to Cipla's wholly owned subsidiary, Cipla USA Inc. An OAI classification indicates that the USFDA found significant compliance issues during its inspection in January 2026. This regulatory status could potentially lead to delays in product approvals or supply disruptions for this specific product line in the US market.
முக்கிய அம்சங்கள்
USFDA classifies Pharmathen International's Rodopi, Greece facility as Official Action Indicated (OAI).The facility is the primary supply partner for Cipla's Lanreotide Injection in the US market.The classification follows previous regulatory updates provided by the company on 7th and 14th January 2026.OAI status signifies that the USFDA may withhold product approvals or take further enforcement actions until remediation is complete.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the OAI status may impact the growth trajectory of Cipla's US specialty portfolio. Monitor management commentary regarding supply continuity and the timeline for remediation at the partner facility.
Jinkushal Industries Q3 FY26 Standalone PAT up 34%; Strategic Shift to Overseas Retail Model
Jinkushal Industries reported a 27% YoY growth in standalone 9M FY26 revenue to ₹184 crores, driven by strong export demand. However, the company reported a consolidated loss of ₹9.87 crores in Q3 FY26, primarily due to a strategic build-up of overseas inventory to ₹70 crores and resulting inter-company profit eliminations. Management is transitioning from a wholesale B2B model to a higher-margin retail-led model, positioning stock closer to end-customers in markets like Mexico and UAE. Despite temporary tax-related deferrals in Mexico, the company maintains its long-term growth trajectory and focus on its proprietary brand, HexL.
முக்கிய அம்சங்கள்
Standalone revenue for 9M FY26 grew 27% YoY to ₹184 croresQ3 FY26 standalone PAT increased by 34% YoY to ₹4.17 croresOverseas inventory surged to ₹70 crores from a historical average of ₹10-15 croresConsolidated Q3 FY26 loss of ₹9.87 crores due to timing differences in profit realization and inter-company eliminationsManagement maintains a target of significant revenue growth over the next 2-3 years
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to monetize the ₹70 crore overseas inventory into retail sales over the next two quarters. The shift to a retail model promises higher margins but introduces longer working capital cycles that require careful observation.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
India Pesticides Q3 FY26 Net Profit Jumps 41% YoY; Revenue Up 31% to INR 229 Crore
India Pesticides Limited reported a strong Q3 FY26 with revenue growing 31% YoY to INR 229 crore and net profit rising 41% to INR 23 crore. For the 9-month period, the company achieved a 44% growth in net profit, driven by robust demand in both export (up 28%) and domestic (up 33%) markets. Management highlighted the commissioning of the Shalvis facility, which is expected to contribute INR 80-100 crore in FY27, supporting the long-term goal of reaching INR 3,000 crore revenue in five years.
முக்கிய அம்சங்கள்
9M FY26 revenue reached INR 808 crore, representing a 27.6% YoY growth with net profit up 44% to INR 89 crore.Q3 EBITDA margins improved to 18% from 17% in the previous year, driven by operating leverage.Shalvis facility expected to scale to INR 1,000 crore revenue over 5 years with 10 planned blocks.Export revenue grew 28% in Q3, with key contributions from the European Union and Australia.Planned capex of INR 105-130 crore for the next financial year to support capacity expansion at Shalvis and Sandila.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the Shalvis facility expansion and the ramp-up in CDMO projects, which are critical to achieving the company's ambitious five-year revenue target. The stock remains a strong play on agrochemical recovery and backward integration.
WIPL Announces Financial Results for the Quarter Ended December 31, 2024
The Western India Plywoods Limited (WIPL) has officially submitted its financial results for the quarter ending December 31, 2024. This filing follows the board's review and approval of the company's performance metrics. As a routine but critical disclosure, it provides transparency into the company's operational health during the third quarter of the fiscal year. Investors should look for the detailed breakdown of revenue and margins in the full report to assess the impact of raw material costs.
முக்கிய அம்சங்கள்
WIPL filed its financial results for the period ending December 31, 2024.The board meeting for the approval of results was concluded on February 5, 2025.The disclosure is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations.The announcement marks the completion of the mandatory quarterly financial reporting cycle.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed profit and loss statement for any signs of margin expansion or contraction. Compare the year-on-year growth figures against industry peers in the wood products sector before making investment decisions.
India Pesticides Q3 PAT Rises 33% YoY to ₹23.11 Cr; CEO Re-appointed for 5 Years
India Pesticides Limited (IPL) reported a strong year-on-year performance for Q3 FY26, with revenue from operations growing 31% to ₹225.93 crore. Net profit for the quarter increased by 33% YoY to ₹23.11 crore, up from ₹17.36 crore in the same period last year. While YoY growth is robust, the company saw a sequential decline in both revenue and profit compared to Q2 FY26. Additionally, the board has ensured leadership stability by re-appointing Mr. Dheeraj Kumar Jain as CEO for a five-year term starting January 2026.
முக்கிய அம்சங்கள்
Revenue from operations increased 31.2% YoY to ₹225.93 crore in Q3 FY26.Net Profit (PAT) grew 33.1% YoY to ₹23.11 crore from ₹17.36 crore in Q3 FY25.9-month FY26 revenue reached ₹790.96 crore compared to ₹621.37 crore in the previous year.9-month FY26 PAT stood at ₹90.53 crore, marking a 41.7% growth over 9M FY25.CEO Dheeraj Kumar Jain re-appointed for a 5-year term effective January 23, 2026.
👀 கவனிக்க வேண்டியவை
The strong year-on-year growth and leadership continuity are positive indicators for long-term investors. However, the sequential (QoQ) decline in margins suggests investors should monitor input cost pressures in the upcoming quarters.
India Pesticides Q3 FY26: PAT Jumps 41% to ₹23 Cr, Revenue Up 31% YoY
India Pesticides Limited (IPL) delivered a strong performance in Q3 FY26, with revenue growing 31% YoY to ₹229 crore, primarily driven by a 32% surge in volumes. EBITDA rose 40% to ₹41 crore, with margins improving to 17.9% despite lower realizations due to price softening in certain molecules. The company is maintaining its growth momentum through a ₹116 crore Capex plan for FY26 and strategic backward integration. Additionally, the shift to renewable energy with a 6 MW solar plant at Sandila is expected to optimize operational costs.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue increased 31% YoY to ₹229 Cr; 9M FY26 Revenue up 28% to ₹808 Cr.PAT for the quarter grew 41% YoY to ₹23 Cr, with EBITDA margins expanding to 17.9%.Overall volume growth of approximately 32% recorded in Q3 FY26, supported by strong order execution.Budgeted Capex of ₹116 Cr for FY26 focused on Sandila and Hamirpur plant expansions.Export sales grew to ₹96 Cr, led by demand in the European Union and Australia.
👀 கவனிக்க வேண்டியவை
Investors should take note of the robust volume growth and margin expansion despite global pricing pressures. The company's focus on backward integration and capacity expansion at Hamirpur provides a clear roadmap for long-term value creation.
Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, underwent a Pre-Approval Inspection (PAI) by the USFDA at its Hauppauge, New York facility from February 2 to February 9, 2026. Upon conclusion, the facility was issued 2 inspectional observations in Form 483. The company has committed to addressing these observations comprehensively within the stipulated timeframe. This inspection is critical as it is a Pre-Approval Inspection, which directly impacts the timeline for new product launches in the US market.
முக்கிய அம்சங்கள்
USFDA conducted a Pre-Approval Inspection (PAI) at the InvaGen facility in Hauppauge, New York.The inspection lasted 8 days, concluding on February 9, 2026.The facility received 2 observations in Form 483 following the audit.InvaGen Pharmaceuticals is a 100% wholly-owned subsidiary of Cipla Limited.Cipla intends to work closely with the USFDA to resolve the issues within the required timeline.
👀 கவனிக்க வேண்டியவை
Investors should monitor for further updates regarding the severity of the 2 observations, as successful resolution is necessary for upcoming product approvals. The low number of observations is generally manageable, but any escalation could delay US market expansion plans.
India Pesticides Re-appoints Dheeraj Kumar Jain as CEO for a 5-Year Term
India Pesticides Limited (IPL) has officially re-appointed Mr. Dheeraj Kumar Jain as the Chief Executive Officer for a second consecutive five-year term. The new term is effective from January 23, 2026, and will extend until January 22, 2031. Mr. Jain is an industry veteran with over 50 years of experience, including more than 30 years with IPL. This move ensures leadership continuity as the company also approved its Q3 FY26 financial results during the same board meeting.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Dheeraj Kumar Jain as CEO and KMP for a 5-year term ending January 2031Mr. Jain brings over 50 years of industry experience and has been with the company for 30+ yearsThe board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025Leadership continuity is maintained as Mr. Jain has served as CEO since 2021
👀 கவனிக்க வேண்டியவை
Investors should view this leadership continuity positively, as it provides stability for the company's long-term R&D and manufacturing strategies. It is also recommended to review the detailed Q3 FY26 financial results released alongside this announcement.
Jinkushal Industries Reports Zero Deviation in Utilization of Rs 116.15 Cr IPO Proceeds
Jinkushal Industries Limited has confirmed zero deviation in the utilization of its IPO proceeds for the quarter ended December 31, 2025. The company raised a total of Rs 116.15 crore, with Rs 104.54 crore coming from the fresh issue. As of the reporting date, Rs 72.13 crore has been utilized for long-term working capital and Rs 21.42 crore for general corporate purposes. The utilization aligns perfectly with the objects stated in the prospectus, as reviewed by the Audit Committee and CARE Ratings.
முக்கிய அம்சங்கள்
Total IPO proceeds raised: Rs 11,615.45 Lakhs (Fresh Issue of Rs 10,454.40 Lakhs).Zero deviation reported in fund utilization compared to the objects stated in the prospectus.Rs 7,213.10 Lakhs deployed for long-term working capital requirements.Rs 2,142.00 Lakhs fully utilized for General Corporate Purposes.Monitoring agency CARE Ratings Limited confirmed no variations in fund usage.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive sign of corporate governance and disciplined capital allocation following the company's recent listing. No further action is required as funds are being deployed as per the original plan.
JKIPL Standalone Revenue Grows 27% to ₹180.32 Cr; Strategic Inventory Build-up to ₹70 Cr
Jinkushal Industries reported a 27% YoY growth in standalone turnover to ₹180.32 crore for the nine months ended December 2025, driven by robust export demand. The company has strategically increased its overseas inventory from historical levels of ₹15 crore to ₹70 crore to enable faster delivery and capture higher margins from refurbished equipment. While consolidated profits are temporarily impacted by inter-company eliminations and a sales deferral in Mexico due to tariff clarifications, the company has successfully diversified into South Africa and the UAE. Management expects consolidated performance to improve significantly as this high-value inventory is monetized in coming quarters.
முக்கிய அம்சங்கள்
Standalone turnover increased 27% YoY to ₹180.32 crore from ₹141.48 crore.Strategic overseas inventory build-up reached a record ₹70 crore to support retail and direct sales.Mexico market experienced temporary demand deferral due to new import tariff clarifications in December 2025.Geographic diversification expanded focus to South Africa and UAE to mitigate regional market risks.IPO proceeds are being actively deployed for brand building and international expansion of the HexL brand.
👀 கவனிக்க வேண்டியவை
Investors should monitor the pace of inventory liquidation at the overseas subsidiary, as converting the ₹70 crore stock into sales is critical for consolidated profitability. Watch for further updates on Mexico's import tariff situation which could impact near-term export volumes.
Cipla Faces GST Inspection at Maharashtra Facilities; Operations Unaffected
The Maharashtra Goods & Service Tax Department initiated inspection and search proceedings at Cipla's facilities and offices on February 5, 2026. The search, conducted under Section 67 of the MGST Act, focuses on tax payments, input tax credit claims, and refunds. While the proceedings are ongoing, the company has stated there is currently no financial impact or disruption to operations. Investors should monitor for any subsequent tax demands or penalties that might arise from this investigation.
முக்கிய அம்சங்கள்
GST Department, Maharashtra initiated search proceedings on February 5, 2026, at 12:30 PM.Investigation covers tax payments, input tax credit (ITC) claims, and refund processes.Action taken under Section 67(1) and 67(2) of the Maharashtra GST Act, 2017.Company reports no immediate financial impact or operational disruption due to the search.
👀 கவனிக்க வேண்டியவை
Monitor for further disclosures regarding any tax demand notices or penalties resulting from this inspection. No immediate sell-off is warranted as operations remain normal.
WIPL Announces Financial Results for Quarter Ended December 31, 2025
The Western India Plywoods Limited (WIPL) has officially submitted its financial results for the quarter and nine-month period ended December 31, 2025. The board met on February 5, 2026, to approve the financial statements, ensuring compliance with regulatory disclosure norms. While specific revenue and profit figures were not detailed in the summary brief, the filing marks a critical periodic update for shareholders. Investors should now look for the detailed line-item performance to assess the company's margin stability in the wood products sector.
முக்கிய அம்சங்கள்
Board meeting concluded on February 5, 2026, to approve Q3 results.Financial results submitted for the period ending December 31, 2025.The announcement confirms adherence to SEBI listing obligations and disclosure requirements.Results cover both the standalone quarter and the cumulative nine-month period of the fiscal year.
👀 கவனிக்க வேண்டியவை
Investors should examine the full financial disclosure for specific trends in raw material costs and net profit margins compared to the previous year. Monitor the stock for any price volatility following the earnings release.
Cipla Q3 FY26: Revenue flat at Rs 7,074 Cr; EBITDA margin dips to 17.7% on Revlimid decline
Cipla reported flat year-on-year revenue of Rs 7,074 crores for Q3 FY26, primarily impacted by a sharp decline in generic Revlimid sales. The One-India business remained a bright spot with 10% growth, while the North America segment recorded $167 million in revenue. Profitability was pressured, with EBITDA margins falling to 17.7% and PAT at Rs 676 crores, which included a Rs 276 crore exceptional item for labor code changes. Management lowered the full-year FY26 EBITDA margin guidance to approximately 21% due to Lanreotide supply disruptions and increased R&D investments.
முக்கிய அம்சங்கள்
Revenue stood at Rs 7,074 crores (flat YoY) with EBITDA margin at 17.7% excluding other income.One-India business grew 10% YoY, with the respiratory segment crossing Rs 5,000 crores in IPM.Lanreotide supply is temporarily paused due to partner FDA issues, with resupply expected only in H1 FY27.R&D spending increased by 37.4% YoY to Rs 494 crores (7% of revenue) to support the future pipeline.Net cash position remains strong at Rs 10,229 crores despite dividend payments and acquisitions.
👀 கவனிக்க வேண்டியவை
Investors should be cautious due to the lowered margin guidance and Lanreotide supply issues, though the strong India growth and healthy cash balance provide long-term support. Monitor the progress of the Indore facility re-inspection and the transition to new leadership under Achin Gupta.
Cipla Announces New Leadership Team and KMP Changes Effective April 1, 2026
Cipla Limited has announced a transition in its Key Managerial Personnel (KMP) and authorized officers, effective from April 1, 2026. The Board has designated Mr. Achin Gupta as the Managing Director and Global CEO, while Mr. Ashish Adukia will serve as the Global CFO. These individuals, along with the Company Secretary and Global General Counsel, are authorized to determine the materiality of events for SEBI disclosures. The announcement follows a board meeting held on January 23, 2026, ensuring a planned leadership succession for the pharmaceutical giant.
முக்கிய அம்சங்கள்
Mr. Achin Gupta appointed as Managing Director and Global CEO effective April 1, 2026Mr. Ashish Adukia designated as the Global Chief Financial OfficerMs. Meera Vanjari (Global General Counsel) and Mr. Rajendra Chopra (CS) included in the authorized KMP listChanges are made under Regulation 30(5) of SEBI Listing Regulations for materiality disclosuresThe board meeting approving these changes concluded at 2:00 p.m. IST on January 23, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition for any changes in corporate strategy or capital allocation under the new leadership. No immediate action is required as the effective date is over two months away.
Cipla Q3 FY26: PAT Drops 57% YoY to ₹676 Cr; EBITDA Margins Contract to 17.7%
Cipla reported a challenging Q3 FY26 with flat revenue growth of 0.02% YoY at ₹7,074 crore. Profitability took a significant hit as EBITDA fell 36.9% to ₹1,255 crore and PAT plummeted 57% to ₹676 crore, impacted by rising material costs and exceptional items. While the India business showed resilience with 10% growth in branded prescriptions, the North America segment faces temporary headwinds due to a manufacturing pause for Lanreotide. The company maintains a very strong balance sheet with a net cash position of ₹10,229 crore.
முக்கிய அம்சங்கள்
Revenue remained nearly flat at ₹7,074 crore compared to ₹7,073 crore in Q3 FY25.EBITDA margins compressed significantly to 17.7% from 28.1% in the previous year's quarter.One India business contributed 49% of total revenue, with Respiratory therapy outperforming the market by 400+ bps.North America revenue stood at $167 million, with Albuterol maintaining a #1 market share of 22%.Net cash position strengthened to ₹10,229 crore, providing significant capital for strategic M&A like the Inzpera acquisition.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of EBITDA margins and the timeline for the re-supply of Lanreotide in the US market. While the India growth story and Pfizer partnership are positive, the sharp decline in quarterly profitability warrants a cautious outlook in the near term.
Cipla's Top-3 US Product Lanreotide Supply Paused Until H1 FY27 Following USFDA Observations
Cipla has confirmed a temporary production halt for Lanreotide Injection, a top-three product for its US subsidiary, following a USFDA inspection of its exclusive supplier, Pharmathen. The inspection at the Greece facility resulted in 9 observations, leading to a pause in manufacturing for remediation efforts. Re-supply to the US market is only expected to resume in the first half of FY 2026-27. This disruption is likely to impact Cipla's US revenue stream significantly until normal operations resume.
முக்கிய அம்சங்கள்
Lanreotide Injection is a top 3 product for Cipla USA, making it a critical revenue driver.Exclusive supplier Pharmathen received 9 USFDA Form 483 observations at its Greece plant.Supply is expected to remain limited until H1 FY 2026-27, indicating a disruption of over 12 months.The company is monitoring supply levels and is committed to remediation to restore stable supply.
👀 கவனிக்க வேண்டியவை
Investors should expect near-term pressure on US sales and margins; monitor management commentary for specific revenue loss estimates and remediation progress.
UNIPLY Uniply Industries Limited
எதிர்மறைதாக்கம் 9/10சட்டம்
Uniply Industries Schedules 18th SCC Meeting to Discuss Liquidation Extension
Uniply Industries Limited, currently undergoing liquidation, has convened its 18th Stakeholders Consultation Committee (SCC) meeting for December 12, 2025. The primary agenda is to discuss the extension of the liquidation period, which is currently slated to end on March 31, 2025. The meeting will also address the resignation of Mr. Anil Patel, a director of Uniply Decor Limited. This indicates that the winding-up process is facing delays and requires more time for asset realization or settlement.
முக்கிய அம்சங்கள்
18th Stakeholders Consultation Committee (SCC) meeting scheduled for December 12, 2025.Proposal to extend the liquidation period beyond the current deadline of March 31, 2025.Discussion on the resignation of Mr. Anil Patel from the board of Uniply Decor Limited.The company is operating under the supervision of Liquidator Santhanam Rajashree.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as liquidation typically results in zero or negligible recovery for equity shareholders. Avoid taking any new positions in the stock as the company is being legally wound up.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
